Navigation Links
74 Percent EBITDA Improvement at Zeltia Group in 2010
Date:2/24/2011

MADRID, Feb. 24, 2011 /PRNewswire/ -- Zeltia Group's net revenues totaled 153.5 million euro in 2010 (approximately 211.4 million USD*), 24.4 percent more than in 2009 (123.4 million euro, or approximately 169.9 million USD). This performance is primarily attributable to a 70 percent increase in Yondelis® sales.

Net sales in the Biopharmaceutical business amounted to 79.4 million euro (approximately 109.3 million USD) in 2010 (51.1 million euro, or approximately 70.3 million USD in 2009), of which 72.1 million (approximately 99.3 million USD) correspond to Yondelis® (43.8 million euro, or approximately 60.3 million USD in 2009).

The Biopharmaceutical segment accounted for 52 percent of total Group revenues in 2010, exceeding for the first time the contribution from the Consumer Chemicals business (73.2 million euro, or approximately 100.8 million USD in 2010, compared with 71.1 million euro, or approximately 97.9 million USD in 2009).

EBITDA improved by 74 percent in 2010 to -3.9 million euro (approximately -5.3 million USD) (-15.3 million euro or approximately -21.0 million USD in 2009).

Net income attributable to the parent company rose 71 percent with respect to 2009.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

This note is also available on the Zeltia web site: www.zeltia.com.

* All original figures are in Euros; dollar figures are estimated using the exchange rate: 1.3773.


'/>"/>
SOURCE Zeltia
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. 34 percent of Galician secondary schools exceed maximum recommended radon levels
2. 34 percent of Galician secondary schools exceed maximum recommended radon levels
3. Codexis Grows Revenue 35 Percent in Third Quarter; Raises 2010 Outlook
4. ReVisions Fenretinide (RT-101) Reduced Incidence of Choroidal Neovascularization by More Than 50 Percent in Patients With Geographic Atrophy in a Phase 2b Trial
5. Tecnalia investigates ecological cement that cuts CO2 emissions by up to 100 percent
6. ClearTrial to Demonstrate How a Top 20 Sponsor Achieved -1 Percent Cost Variance Across Their $130M Clinical Portfolio at Major Industry Conference
7. In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market
8. ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line
9. Recently Approved Onglyza Is Covered by 44 Percent of Commercial Health Plans But Less Than One Percent of Medicare Plans for The Treatment of Type 2 Diabetes
10. New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials
11. Nearly 70 Percent of Health Professionals Support Biotechnologys Use in Food Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... ProMIS Neurosciences (“ProMIS” ... first three targets, it has identified a fourth in a series of novel ... development and progression of Alzheimer’s disease (AD). , “This discovery is ...
(Date:5/4/2016)... 4, 2016  Bayer today announced that a ... ® (regorafenib) tablets for the treatment of ... its primary endpoint of a statistically significant improvement ... the efficacy and safety of regorafenib in patients ... with sorafenib. The safety and tolerability were generally ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... biotechnology to help treat hormonal and stress related hair loss. With patent-pending formulas ... hearts of key opinion leaders in the medical and salon channels nationwide. ...
(Date:5/3/2016)... Boston, Massachusetts (PRWEB) , ... May 03, 2016 ... ... communities will gather at Boston CEO 2016 on May 31st and June 1st ... off-the-record networking forum for leading executives in the life sciences, offering exclusive access ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
(Date:3/17/2016)... , March 17, 2016 ABI ... intelligence, forecasts the global biometrics market will reach ... impressive 118% increase from 2015. Consumer electronics, particularly ... embedded fingerprint sensors anticipated to reach two billion ... Dimitrios Pavlakis , Research Analyst at ...
Breaking Biology News(10 mins):